Fresenius Medical Care AG

Fresenius Medical Care AG(FMS)股票分析

$23.100

-0.169 (-0.73%)收盘时

Loading chart…
High
23.240
Open
23.160
VWAP
23.08
Vol
715.63K
Mkt Cap
11.25B
Low
22.910
Amount
16.52M
EV/EBITDA, TTM
5.93

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.

AI analysis of Fresenius Medical Care AG (FMS)

hold

Fresenius Medical Care AG is currently priced at $23.10, which is below several analyst price targets, including $25 from Truist and $32.30 from JPMorgan. However, the stock has a low RSI of 24.23, indicating it is oversold, which could present a buying opportunity. The main risk is its declining U.S. treatment growth, which fell by 0.9%, suggesting potential challenges ahead.

估值指标

The current forward P/E ratio for Fresenius Medical Care AG (FMS) is 9.69, compared to its 5-year average forward P/E of 13.03.

Forward P/E

Fair
5Y Average P/E
13.03
Current P/E
9.69
高估
16.63
低估
9.42

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
7.26
Current EV/EBITDA
5.93
高估
8.20
低估
6.32

Forward P/S

Fair
5Y Average P/S
0.64
Current P/S
0.61
高估
0.78
低估
0.51

Whales holding FMS

P

Pzena Investment Management, Inc.

+ HoldingFMS

+9.97%

3M Return

F

Fiduciary Management, Inc.

+ HoldingFMS

+5.10%

3M Return

事件时间线

2026-05-28 (ET)

07:10:00

Fresenius Medical Care Launches €1B Share Buyback Program

2026-05-26 (ET)

07:10:00

Fresenius Medical Care Plans €1B Share Buyback

2026-05-20 (ET)

13:10:00

Fresenius Medical Care Reappoints CFO Martin Fischer Until 2031

2026-05-05 (ET)

07:50:00

Fresenius Medical Care Expects Flat Revenue Growth in 2026

07:50:00

Fresenius Medical Care Reports Q1 Revenue of EUR 4.612B

资讯

FMS FAQ — answered by Alphio AI

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers. It operates in the Healthcare sector.

Fresenius Medical Care AG is currently priced at $23.10, which is below several analyst price targets, including $25 from Truist and $32.30 from JPMorgan. However, the stock has a low RSI of 24.23, indicating it is oversold, which could present a buying opportunity. The main risk is its declining U.S. treatment growth, which fell by 0.9%, suggesting potential challenges ahead.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始